Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.
Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.
复制标题
DOI：
10.4061/2010/610613
复制
发表时间：
2010-07-08
影响因子：
--
通讯作者：
Blennow, Kaj
中科院分区：
文献类型：
--
作者：
Mattsson, Niklas;Zetterberg, Henrik;Blennow, Kaj
Several single-center studies have confirmed the usability of cerebrospinal fluid (CSF) biomarkers for the diagnosis of Alzheimer's disease (AD), even in early disease stages. Large scale multicenter studies have principally confirmed this, although such studies have also indicated the presence of significant intercenter and interlaboratory variations in biomarker measurements. Such variations may hamper the development of biomarkers and their introduction into clinical routine practice. Recently a quality control program run by the Alzheimer's Association was started in order to harmonize procedures of laboratories world-wide. This program provides both standardized guide lines and external control CSF samples, and will allow longitudinal evaluation of laboratory performance.
